Information Provided By:
Fly News Breaks for June 8, 2016
OSIR
Jun 8, 2016 | 11:58 EDT
Piper Jaffray analyst Edward Tenthoff suspended his rating on Osiris Therapeutics pending "greater clarity" into the company's outstanding accounting issues and Justice Department/SEC investigations. Tenthoff had an Overweight rating on the shares with a $12 price target.
News For OSIR From the Last 2 Days
There are no results for your query OSIR